BSBenedito Borges da Silva

Benedito Borges da Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Benedito Borges da Silva has a total of 245 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Systematic review of insulin-like growth factor 1 gene expression in women with breast cancer

    by Danylo Rafhael Costa-Silva, Maria da Conceição Barros-Oliveira, Benedito Borges da Silva


  • Open Access

    Expression of metalloproteinases 2 and 9 and plasma zinc concentrations in women with fibroadenoma

    by Luana Mota Martins, Igor Sabino Barros, Emanuelle de Sousa Ferreira, Antonio Gomes da Silva Neto, Carla Solange de Melo Escórcio Dourado, Victor Alves de Oliveira, Ana Raquel Soares de Oliveira, Jennifer Beatriz Silva Morais, Dilina Do Nascimento Marreiro, Benedito Borges da Silva

    OBJECTIVE: This study aims to investigate the association between the immunohistochemical expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and plasma zinc in women with fibroadenoma. METHODS: This cross-sectional study included 37 premenopausal women with fibroadenoma. Waist circumference and body mass index of the participants were measured. Plasma zinc concentrations were determined using atomic flame absorption spectrophotometry. Fragments of breast tissue were fixed and incubated with primary mouse monoclonal antibodies (monoclonal antibodies matrix metalloproteinase-2-507 and monoclonal antibodies matrix metalloproteinase -9-439). Semi-quantitative analysis of matrix metalloproteinase-2 and matrix metalloproteinase-9 immunoreactivity was performed. Spearman's test and Friedman's test were used for statistical analyses. The p<0.05 were considered statistically significant. RESULTS: The average age of the participants was 32.81 +/- 9.51 years. The body mass index and waist circumference values were within the normal range. The mean plasma zinc concentration was 42.73 +/- 13.84 mu g/dL, with 94.6% inadequacy. A statistically significant difference was found between the positive expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 (p=0.0184). There was no significant correlation between the matrix metalloproteinase expression and the plasma zinc levels. CONCLUSIONS: Women with fibroadenoma had hypozincemia and positive expression of metalloproteinases.


  • Open Access

    Evaluation of the association of ERCC2 rs13181 polymorphism with different types of gliomas in patients in Northeast Brazil

    by Cléciton Braga Tavares, Larysse Cardoso Campos-Verdes, Pedro Vitor Lopes-Costa, Frsancisca das Chagas Sheyla Almeida Gomes-Braga, Elmo Jesus Nery Junior, Carla Solange Melo Escórcio-Dourado, Alesse Ribeiro Santos, Emerson Brandao Sousa, Renato Oliveira Pereira, Luiz Henrique Gebrim, et al.

    Gliomas are the most common primary tumors of the central nervous system with unclear etiology. However, hereditary factors may play an important role in glioma development, with mutations and single nucleotide polymorphisms (SNPs) being prominent among the genetic changes. This study aimed to evaluate the association of the ERCC2 gene rs13181 variant polymorphism between high- and low-grade gliomas in patients from Brazil’s Northeast region. Samples from glioma patients stored in paraffin blocks were used. DNA extraction was performed using the MagMAX™ FFPE DNA/RNA Ultra kit, and for genotyping, the Taqman assay probe C_3145033_10 corresponding to the SNP rs13181 of the ERCC2 gene was selected. Quantitative and categorical variables were analyzed using the t-test and Fisher’s exact test or Chi-square test (p < 0.05). Patients with low-grade gliomas were younger than those with high-grade gliomas (p = 0.003). Statistically significant differences were not observed in the expression of the GG, GT, and TT genotypes between low- and high-grade gliomas. The ERCC2 rs13181 genotypes found were TT, GG, and GT; however, no difference in the expression between different glioma types was observed.

  • Open Access

    Authors' Reply “Comments: Evaluation of the accuracy of mammography, ultrasound, and magnetic resonance imaging in suspect breast lesions”

    by Renato de Oliveira Pereira, Larissa Almondes da Luz, Diego Cipriano Chagas, Jefferson Rodrigues Amorim, Elmo de Jesus Nery-Junior, Araci Castelo Branco Rodrigues Alves, Flávio Teixeira de Abreu-Neto, Maria da Conceicão Barros Oliveira, Danylo Rafhael Costa Silva, José Maria Soares-Júnior, et al.

  • Open Access

    Influence of CYP19A1 gene expression levels in women with breast cancer: a systematic review of the literature

    by Maria da Conceição Barros-Oliveira, Danylo Rafhael Costa-Silva, Alesse Ribeiro dos Santos, Renato Oliveira Pereira, José Maria Soares-Júnior, Benedito Borges da Silva

    Breast cancer is the most frequently diagnosed malignant neoplasm in women and is considered a multifactorial disease of unknown etiology. One of the major risk factors is genetic alteration. Changes in CYP19A1 gene expression levels have been associated ...


  • Open Access

    Critical imaging analysis of suspicious non-palpable breast lesions

    by Renato de Oliveira Pereira, Benedito Borges da Silva

    Screening programs using MMG seem to result in a general decline in breast cancer mortality and recommendations that women over the age of 40 should undergo annual screening mammography have led to an increasing number of diagnoses of non-palpable breast lesions 8 . The first sign of non-palpable breast cancer may be calcifications, and MMG is currently the best modality to detect microcalcifications. Furthermore, breast cancer cases that are manifested as focal asymmetric densities, also evaluated by this method, tend to be non-palpable lesions. On the other hand, excessive diagnosis of architectural distortions (distortions of the breast parenchyma without a defined mass) leads to lower mammographic specificity 9,10 . It is important to consolidate and disseminate screening programs, still deficient in underdeveloped and developing countries, technical improvements, and adequate training of radiologists to recognize the imaging characteristics and behavior of these lesions so that MMG can be used in the diagnosis 7 .

  • Open Access

    Influence of Insulin-Like Growth Factor 1 Gene Expression in Women with Breast Cancer: A Systematic Review

    by Danylo Rafhael Costa-Silva, Maria da Conceição Barros-Oliveira, Larysse Cardoso Campos-Verdes, Renato de Oliveira Pereira, Cleciton Braga Tavares, Mariella de Almeida Melo, Fidelis Manes Neto, Arquimedes Cavalcante Cardoso, Eid Gonçalves Coelho, Edison de Araujo Vale, et al.

    Background: Breast cancer, the leading cause of cancer death among women worldwide, one of the major risk factors for breast cancer is genetic changes. Changes in the expression levels of the insulin-like growth factor 1 (IGF-1) gene have been associated with increased risk and aggressiveness of breast cancer. The IGF-1 gene encodes the IGF-1 peptide that is present in most human tissues, as in the normal and neoplastic mammary gland. Here, we conducted a systematic review to investigate the influence of IGF-1 gene expression levels in women with breast cancer.Methods: PubMed, Scopus, and Web of Science databases were searched for relevant studies published between February 2 and May 15, 2019, using inclusion and exclusion criteria in accordance with PRISMA guidelines. We analyzed the studies to find association between IGF-1gene expression and breast cancer.Results: A growing number of studies in women with breast cancer support, with controversial results, the influence of IGF-1 gene expression levels on clinical-pathological factors, disease-free survival, overall survival, and resistance to tamoxifen.Conclusions: Therefore, the elucidation of IGF-1 gene expression patterns through further studies may enable the characterization of women at high risk for breast cancer, as well as the development of effective prognostic and therapeutic strategies.

  • Open Access

    Assessment of IGF-1 expression in the peripheral blood of women with recurrent breast cancer

    by Danylo Rafhael Costa-Silva, Maria Da Conceição Barros-Oliveira, Francisco Adelton Alves-Ribeiro, Larysse Cardoso Campos-Verdes, Elmo De Jesus Nery Junior, Samara Fernanda Vieira-Valença, Rodrigo Jose De Vasconcelos-Valença, Veronica Mendes Soares, André Luiz Pinho-Sobral, Emerson Brandão Sousa, et al.

    Breast cancer is the most common malignancy affecting women worldwide. The insulin-like growth factor 1 (IGF-1) gene encodes a protein responsible for a wide variety of physiological processes, including differentiation and cell proliferation. Despite several studies on tumor tissues, no study has evaluated IGF-1 expression in the peripheral blood of women with recurrent breast cancer. In this cross-sectional study, IGF-1 expression in the peripheral blood of 146 women with breast cancer treated approximately 5 years ago was quantified by quantitative reverse transcription polymerase chain. The women were divided into 2 groups: non-recurrence (n = 85) and recurrence (n = 61). Statistical analysis of the data was performed using ANOVA, Mann–Whitney, and Chi-squared tests (P < .05). The results showed no significant difference in IGF-1 expression between the non-recurrence and recurrence groups (P = .988). In the subgroups of patients with lymph node involvement, no statistically significant difference was observed in IGF-1 expression between women with recurrence and those non-recurrence (P = .113). In patients without lymph node metastases, IGF-1 messenger ribonucleic acid (mRNA) expression levels were significantly higher in the non-recurrence group than in the recurrence group (P = .019). Furthermore, using the median IGF-1 mRNA expression as the cutoff point, it was obtained a statistically significant difference in tumor histological grade among women with recurrent breast cancer (P = .042). These data showed significantly higher IGF-1 expression in women without lymph node metastases in the non-recurrence group compared with the recurrence group. In addition, a significant difference was observed in median IGF-1 mRNA expression in relation to tumor histological grade in women with recurrent breast cancer.


  • Open Access

    Influence of Insulin-Like Growth Factor 1 Gene Expression in Women with Breast Cancer: A Systematic Review

    by Danylo Rafhael Costa-Silva, Francisco Adelton Alves-Ribeiro, Maria da Conceição Barros-Oliveira, Larysse Cardoso Campos-Verdes, Renato de Oliveira Pereira, Cleciton Braga Tavares, Mariella de Almeida Melo, Arquimedes Cavalcante Cardoso, Eid Gonçalves Coelho, Pedro Vitor Lopes-Costa, et al.

    Background: Breast cancer, the leading cause of cancer death among women worldwide, one of the major risk factors for breast cancer is genetic changes. Changes in the expression levels of the insulin-like growth factor 1 (IGF-1) gene have been associated with increased risk and aggressiveness of breast cancer. The IGF-1 gene encodes the IGF-1 peptide that is present in most human tissues, as in the normal and neoplastic mammary gland. Here, we conducted a systematic review to investigate the influence of IGF-1 gene expression levels in women with breast cancer.Methods: PubMed, Scopus, and Web of Science databases were searched for relevant studies published between February 2 and May 15, 2019, using inclusion and exclusion criteria in accordance with PRISMA guidelines. We analyzed the studies to find association between IGF-1gene expression and breast cancer.Results: A growing number of studies in women with breast cancer support, with controversial results, the influence of IGF-1 gene expression levels on clinical-pathological factors, disease-free survival, overall survival, and resistance to tamoxifen.Conclusions: Therefore, the elucidation of IGF-1 gene expression patterns through further studies may enable the characterization of women at high risk for breast cancer, as well as the development of effective prognostic and therapeutic strategies.

  • Open Access

    Association of XRCC1 rs1799782 and ERCC2 rs13181 Polymorphisms with Glioma Risk: A Systematic Review and Meta-Analysis

    by Cléciton Braga Tavares, Francisco Adelton Alves-Ribeiro, Elmo de Jesus Nery Junior, Rodrigo Jose de Vasconcelos-Valença, Larysse Cardoso Campos-Verdes, Francisca das Chagas Sheyla Almeida Gomes-Braga, Pedro Vitor Lopes-Costa, Alesse Ribeiro dos Santos, André Luiz Pinho-Sobral, Viriato Campelo, et al.

    BackgroundGliomas are the most common primary tumors of the central nervous system with unclear etiology, however hereditary factors may play important roles in the development of gliomas with mutations and single nucleotide polymorphisms (SNPs) being prominent among the genetic changes. this systematic review and meta-analysis assess the association of XRCC1 (rs1799782) and ERCC2 (rs13181) gene polymorphisms and glioma risk.MethodsThis study included articles indexed in the PUBMED and EMBASE databases published during the past 15 years. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed. The PICOS model was used to develop the inclusion criteria and search terms. This review was recorded at PROSPERO International prospective register of systematic reviews, ID 196173. The META-MAR V2.7.0 meta-analysis calculator was used for the statistical analysis with p-values < 0.05 being considered statistically significant. Dichotomous data are presented as odds ratios (OR) with a 95% confidence interval (CI). Statistical heterogeneity was measured using the I2 test and I2 > 50% were regarded as high heterogeneity. Funnel plots, Begg (BT) and Egger Tests (ET) were used to assess publication bias (pResults Literature review identified 10 articles on ERCC2 gene rs13181 variant and 11 on XRCC1 rs1799782. The meta-analysis identified a risk for gliomas for the TT genotype of the XRCC1 rs1799782 SNP in Asians (OR: 1.59, 95% CI: 1.3-1.93; p=0.006; I2 13.1%). ERCC2 rs13181 polymorphisms identified as risks for gliomas were AC genotypes in Asians (OR: 2.06, 95% CI: 1.75-1.42; p = 0.00057; I2 91.1%) and Caucasians (OR: 1.16, 95% CI: 1.01-1.31; p = 0.02; I2 12.2%), and CC genotypes in Caucasians (OR: 2.06, 95% CI: 1.75-1.42; p = 0.0001; I2 98.9%).Conclusions TT genotypes of the XRCC1 rs1799782 SNP in Asians, AC genotypes of ERCC2 rs13181 polymorphisms in Asians and Caucasians, and CC genotypes of ERCC2 rs13181 polymorphisms in Caucasians were associated with increased risk for gliomas that may benefit these patients with early diagnostic and therapeutic strategies.